284 related articles for article (PubMed ID: 27267143)
1. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.
Staals EL; Ferrari S; Donati DM; Palmerini E
Eur J Cancer; 2016 Aug; 63():34-40. PubMed ID: 27267143
[TBL] [Abstract][Full Text] [Related]
2. Treatment updates on tenosynovial giant cell tumor.
Palmerini E; Staals EL
Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
[TBL] [Abstract][Full Text] [Related]
3. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
Brahmi M; Vinceneux A; Cassier PA
Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
[TBL] [Abstract][Full Text] [Related]
4. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Palmerini E; Longhi A; Donati DM; Staals EL
Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
[TBL] [Abstract][Full Text] [Related]
5. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
Ravi V; Wang WL; Lewis VO
Curr Opin Oncol; 2011 Jul; 23(4):361-6. PubMed ID: 21577109
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
[TBL] [Abstract][Full Text] [Related]
7. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
8. Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
Mastboom MJL; Hoek DM; Bovée JVMG; van de Sande MAJ; Szuhai K
Histopathology; 2019 Jan; 74(2):332-340. PubMed ID: 30152874
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT.
Spierenburg G; Grimison P; Chevreau C; Stacchiotti S; Piperno-Neumann S; Le Cesne A; Ferraresi V; Italiano A; Duffaud F; Penel N; Metzger S; Chabaud S; van der Heijden L; Pérol D; van de Sande MAJ; Blay JY; Gelderblom H
Eur J Cancer; 2022 Sep; 173():219-228. PubMed ID: 35932628
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
[TBL] [Abstract][Full Text] [Related]
11. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
12. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis.
Thongchot S; Duangkaew S; Yotchai W; Maungsomboon S; Phimolsarnti R; Asavamongkolkul A; Thuwajit P; Thuwajit C; Chandhanayingyong C
Hum Cell; 2023 Jan; 36(1):456-467. PubMed ID: 36456782
[TBL] [Abstract][Full Text] [Related]
13. RNAscope CSF1 chromogenic in situ hybridization: a potentially useful tool in the differential diagnosis of tenosynovial giant cell tumors.
Thangaiah JJ; Koepplin JW; Folpe AL
Hum Pathol; 2021 Sep; 115():1-9. PubMed ID: 34058245
[TBL] [Abstract][Full Text] [Related]
14. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
Spierenburg G; van der Heijden L; van Langevelde K; Szuhai K; Bovée JVGM; van de Sande MAJ; Gelderblom H
Expert Opin Ther Targets; 2022 Apr; 26(4):333-345. PubMed ID: 35443852
[TBL] [Abstract][Full Text] [Related]
15. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
Chan AS; Katiyar V; Dy P; Singh V
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
[TBL] [Abstract][Full Text] [Related]
16. Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor.
Tap WD; Healey JH
Tumour Biol; 2022; 44(1):239-248. PubMed ID: 36502356
[TBL] [Abstract][Full Text] [Related]
17. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
[TBL] [Abstract][Full Text] [Related]
18. The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT.
Mastboom MJL; Lips W; van Langevelde K; Mifsud M; Ng C; McCarthy CL; Athanasou NA; Gibbons CLMH; van de Sande MAJ
Surg Oncol; 2020 Dec; 35():261-267. PubMed ID: 32932224
[TBL] [Abstract][Full Text] [Related]
19. Randomized placebo-controlled double-blind phase II study of zaltoprofen for patients with diffuse-type and unresectable localized tenosynovial giant cell tumors: a study protocol.
Takeuchi A; Nomura A; Yamamoto N; Hayashi K; Igarashi K; Tandai S; Kawai A; Matsumine A; Miwa S; Nishida Y; Nakamura T; Terauchi R; Hoshi M; Kunisada T; Endo M; Yoshimura K; Murayama T; Tsuchiya H
BMC Musculoskelet Disord; 2019 Feb; 20(1):68. PubMed ID: 30738433
[TBL] [Abstract][Full Text] [Related]
20. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature.
Giustini N; Bernthal NM; Bukata SV; Singh AS
Clin Sarcoma Res; 2018; 8():14. PubMed ID: 30002809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
